PIA Executive Committee:

Biofluid Based Biomarkers


Chair: Henrik Zetterberg, MD

Henrik Zetterberg is a Professor of Neurochemistry at the University of Gothenburg, Sweden, and University College London, UK, and a Clinical Chemist at the Sahlgrenska University Hospital in Gothenburg. He is Head of the Department of Psychiatry and Neurochemistry at the University of Gothenburg, and his main research focus and clinical interest is fluid biomarkers for central nervous system diseases, Alzheimer’s disease in particular. He has published more than 900 papers and has received numerous awards.  

Vice Chair: Charlotte Teunissen, PhD

Charlotte Teunissen’s mission is l, i.e. to improve care of patients with neurological diseases by developing body fluid biomarkers for diagnosis, stratification, prognosis and monitoring treatment responses. In fact she started with this line of research at the beginning of her PhD thesis. Her studies cover the entire spectrum of biomarker development. The group (>30 researchers) starts with biomarker identification, hypothesis based as well as by -omics methods. They put strong effort in assay development and analytical validation for the most promising biomarkers. In the next step, the group performs extensive internal and external clinical validation to ultimately arrive at implementation of biomarkers in clinical practice. Her lab has In house state of the art technologies, such as Quanterix ultrasensitive SimOA technology, Mesoscale technology, Western Blot and in vitro technologies for clinical routine lab analysis. These studies are all facilitated due to Charlotte’s responsibility for a large well-characterised biobank, of >4000 paired CSF and serum samples of dementia patients (a.o. Alzheimer, Frontotemporal, Lewy Bodies) and controls with subjective complaints, that visit the memory clinic Alzheimer Center Amsterdam. To ensure the quality of our biosamples, they perform scientific studies to detect e.g. sentinel biomarkers, and the lab and biobank are CLIA and ISO15189 certified. Charlotte has always collaborated strongly in the field, as she states that collaboration is a prerequisite for performing high quality biomarker studies, visible in her lead in several standardization efforts, the BioMS network and now in the Society for Neurochemistry and routine CSF analysis and the Alzheimer Association-Global Biomarker Standardization consortium.

Programs Chair/Executive Committee Member: Andreas Jeromin, PhD

Andreas Jeromin, PhD, has led biomarker programs with increased responsibility in academia and industry for more than 25 years. He is co-author of more than 200 publications and a member of several strategic biomarker efforts. Andreas Jeromin is a medical and scientific advisor to Quanterix Corp.

Communications Chair:  Fabricio Oliveira MD, PhD
Fabricio Ferreira de Oliveira, MD, BBA, MSc, PhD, is an Affiliate Professor of the Department of Neurology and Neurosurgery of the Federal University of São Paulo, a Medical Doctor (MD) and a Bachelor in Business Administration (BBA), Elected Member of the ISTAART Advisory Council (Alzheimer's Association, 2018-2020) and of the Executive Committee of the Biofluid Based Biomarkers Professional Interest Area (ISTAART, 2018-2020), Master of Sciences (MSc) in Medical Sciences (Neurology), Philosopher Doctor (PhD) in Medicine (Neurology), Post-Doctoral Fellow from The State of São Paulo Research Foundation - FAPESP, Internist at the A. C. Camargo Cancer Center in São Paulo, HealthCare Council Member for Gerson Lehrman Group. He is certified by the Medical Council of the State of São Paulo and the Brazilian Academy of Neurology as an expert in Internal Medicine (Medical Residency at the Federal University of Rio de Janeiro: 03/2000-02/2002) and Neurology (Medical Residency at the State University of Campinas: 02/2005-01/2007). He was previously a senior physician (2002-2004) and the leader of the Brain Injured Patients' Rehabilitation Program (4th floor - 64 beds) at the SARAH Network of Rehabilitation Hospitals - SARAH Brasília. His medical graduation was from 1994 to 1999 at the State University of Rio de Janeiro, and his business administration graduation was from 2006 to 2009 at the Pontifical Catholic University of Campinas. He is a member of the International Society to Advance Alzheimer's Research and Treatment - ISTAART, of the International Parkinson and Movement Disorder Society - MDS, of the American Academy of Neurology, and of the Brazilian Academy of Neurology. He has been awarded several international awards in the field of Neurology, and has been a member of the editorial board and/or reviewer for dozens of international medical journals, for the de Leon Prize in Neuroimaging and the Alzheimer Award, besides advising the Ministry of Health, The State of Rio Grande do Sul Research Foundation - FAPERGS and The State of Tocantins Research Foundation - FAPT in Brazil, as well as the Times Higher Education World Reputation Rankings, the Elsevier Advisory Panel and the Kudos Preview Program, and reviewing abstracts for the AAIC - Alzheimer's Association International Conference, for the AIC - Alzheimer's Imaging Consortium, and for the Technology and Dementia PreConference.

Executive Committee Member:  Laura Baker, PhD
Dr. Laura Baker is Associate Director of the NIA Wake Forest Alzheimer’s Disease Center that supports existing and new research focused on cerebrovascular and metabolic contributions to Alzheimer’s, and new strategies to prevent and treat the disease. Dr. Baker also leads efforts for the Center to provide Alzheimer-related education and resources for the community and healthcare providers in North Carolina, and for other groups across the U.S. One primary focus in these efforts is to increase diversity of participants enrolled in Alzheimer’s research.

Over the past 25 years, Dr. Baker’s research has focused on identifying new ways to slow and prevent the disease in older adults. In the last 15 years, her focus has been on lifestyle interventions that have the potential to restore health not only for the body, but also for the brain. This approach is gaining popularity among scientists as one of our most promising interventions with the potential to prevent or slow disease.

Dr. Baker is now leading two large national clinical trials to test whether lifestyle interventions can protect brain health in older adults at increased risk for cognitive decline and dementia. The EXERT trial tests the effects of moderate/intense aerobic exercise on cognition and Alzheimer brain biomarkers in adults with mild cognitive impairment, and U.S. POINTER, modeled on the Finnish FINGER study, will test whether an intensive lifestyle intervention that involves exercise, diet, cognitive stimulation, and increased medical monitoring protects brain health in cognitively normal but at risk older adults.

Executive Committee Member: Kaj Blennow, MD, PhD
Kaj Blennow is MD, and holds a Specialist Competence in General Psychiatry and in Cinical Chemistry.  He is Professor and Academic Chair in Neurochemistry at University of Gothenburg, and Head of the Clinical Neurochemistry Lab at Sahlgrenska University Hospital, Gothenburg, Sweden. Prof Blennow holds the Torsten Söderberg Professorship at the Royal Swedish Academy of Sciences.

Dr. Blennow has published more than 1000 original research papers and 150 review articles in peer-reviewed journals, and has an H-index of 119.

He is President of the Society for CSF analysis and Clinical Neurochemistry, head of the Alzheimer’s Association QC program for CSF biomarkers and Chair of the International Federation of Clinical Chemistry (IFCC) working group on CSF proteins.

He has received several scientific awards, such as The CINP Award (1992), the IPA Research Award (1993), the Alois Alzheimer Research Award (2001), the ECNP Clinical Research Award (2010), the Henry Wisniewski Lifetime Achievement Award in Alzheimer’s Disease Research (2011), and the The International Foundation for Research in Alzheimer’s Disease European Grand Prix in Research (2013), and the Söderberg Price in Medicine at the Swedish Society for Medicine (2016), and the Nordic Prize in Medicine.

Executive Committee Member: Sylvain Lehmann, MD, PhD  
Prof. Sylvain Lehmann was trained as an M.D. (1991, Strasbourg University, School of Medicine, Fr) and a Ph.D. (1992: Cellular and Molecular Biology). He was the recipient of a Howard Hughes fellowship for physician and spent four years in Washington University, USA as a postdoctoral fellow and a research assistant professor (1993-1996). There he started working on Prion and Alzheimer Disease using cell culture and cell biological tools. From 1997-2002 he was an INSERM Senior Researcher and in 2003 obtained a position of professor of Biochemistry at the Medical School of Montpellier. His clinical unit at the University Hospital Center (CHU) of Montpellier is in charge of the biological diagnosis of neurodegenerative disorders and he recently set up a reference Neurological biobank. His laboratory integrates the “Clinical Proteomics Platform” of the CHU and is involved in innovative program on biomarker discovery and detection using mass spectrometry and biochips. He has a long experience in national and international program as coordinator and partner of French and EU programs.  He is the vice-president of the “Société Française de Biologie Clinique”(SFBC) and the head of the Montpellier Center of Excellence in Neurodegenerative Diseases (http://www.coen.org/). His current research interest is in the development and validation of innovative approaches (mass spectrometry, ultrasensitive, conformational assays, AI) to discover and validate biofluid biomarkers in Alzheimer’s disease and related disorders.

Executive Committee Member: Piotr Lewczuk

Prof. Piotr Lewczuk leads the Laboratory for Clinical Neurochemistry and Neurochemical Dementia Diagnostics at the Department of Psychiatry and Psychotherapy, Universitätsklinikum Erlangen, Germany, an ISO 15189 accredited lab, recognized as one of the leading centers for neurochemical diagnosis of neurodegenerative disorders. For more than 25 years Dr. Lewczuk has been working on diagnostic and research aspects of cerebrospinal fluid (CSF) analysis, including a broad range of neurologic and psychiatric disorders (multiple sclerosis and other neuroinflammations, acute and chronic neuroinfections, stroke, etc.), with a particular scope on neurodegeneration and major focus on Alzheimer's Disease (AD). Dr. Lewczuk has been member of the Extended Executive Board of the German Society for Clinical Neurochemistry and CSF Analysis (DGLN) for more than 10 years, and a co-founder and member of the Advisory Board of the international Society for CSF Analysis and Clinical Neurochemistry. Between 2012 and 2015 he co-chaired the Global Biomarkers Standardization Consortium (GBSC), and currently is member of the Executive Committee of the Biofluid Based Biomarkers (BBB) PIA of the Alzheimer's Association. For several years Dr. Lewczuk has been associate and senior editor of the Journal of Alzheimer's Disease, and since 2017 he has been a co-leader of the Task Force Biological Markers of the World Federation of the Societies of Biological Psychiatry. Dr. Lewczuk has published more than 180 publications and book chapters, and has edited special issues of journals focusing on diagnostics of AD. For several years he has been cooperating with and consulting world-wide leading biotech companies, including Roche, Fujirebio/Innogenetics, 
IBL International, and AJ Roboscreen.

Executive Committee Member: Robert Rissman, PhD   

The goal of my research is to investigate the mechanisms underlying neuropathology in various neurodegenerative diseases. The lab was initially focused on Alzheimer's Disease (AD) and understanding how central corticotropin-releasing factor (CRF) pathways interplay with peripheral stress signaling and contribute to neuronal vulnerability and AD neuropathology. In addition to this ongoing work we also study the mechanistic pathways that link Parkinson's Disease (PD) pathology (e.g. synuclein) to AD in animal models. In terms of novel biomarker discovery, our lab has a large focus on understanding the role of neuronal exosomes and other blood based biomarkers in diagnosing AD and PD. For all our work we use transgenic mice, in vivo pharmacology and human postmortem tissues.  

I am the founding and current Director of the Biomarker Core for the Alzheimer’s Disease Cooperative Study (ADCS). In 2018, the UCSD ADCS NIA grant (1991-2018) was replaced by the NIA Alzheimer’s Clinical Trials Consortium (ACTC) grant which was awarded to Dr. P. Aisen at USC ATRI in San Diego. I established the USC ATRI Biomarker Division/Core in San Diego in 2017 as a stand alone facility comprised by a wet laboratory and a biospecimen bank. The biospecimen bank team processes blood and CSF samples from patients who participate in ATRI and ACTC trials.

I am the Director of UCSD's Alzheimer's Disease Research Center (ADRC) neuropath core. The core collects postmortem brain specimens from participants who are enrolled in UCSD's longitudinal study. Core neuropathologists analyze the tissues and document all relevant pathologies. Post analysis all tissues are available for sharing for research projects. Fresh frozen, fixed tissues, DNA, CSF &plasma are available.

Junior Research Member: Marta del Campo, PhD    

Dr. Marta del Campo obtained her PhD in 2015 as part of the prestigious Erasmus Mundus Joint doctorate program at the VUmc in Amsterdam and in collaboration with the University of Coimbra. Her main scientific interest is to understand the proteostasis changes that underlie the different dementias and translate this knowledge into applicable diagnostic tests and potential therapeutic targets. Dr. del Campo has collaborated with high-qualified researchers from different national and international institutes. She has participated in the organisation of international conferences and reviewed multiple scientific journals and competitive grant proposals. The work published by Dr. del Campo reflects her ability to perform multidisciplinary projects involving molecular, pathological and clinical data. Dr. del Campo is committed to perform and promote translational research to ultimately contribute on the development of scientific knowledge within the field of dementia.   

Immediate Past Chair:  Michelle Mielke, PhD

Michelle M. Mielke, Ph.D. received a Bachelor’s of Science in Neuroscience at the University of Pittsburgh and a doctorate in Neuroepidemiology from the Johns Hopkins University Bloomberg School of Public Health. She is currently a Professor in the Department of Health Sciences Research, Division of Epidemiology, and a Professor in the Department of Neurology at the Mayo Clinic in Rochester, MN. Dr. Mielke works as a translational epidemiologist to further understanding of the etiology and epidemiology of neurodegenerative diseases. A primary focus of her research is the identification of fluid biomarkers for the diagnosis, prediction, and progression of Alzheimer's disease and other neurodegenerative diseases. Another focus of Dr. Mielke’s research is on understanding the sex and gender differences in the development and progression of neurodegenerative diseases. She directs the Mayo Clinic Specialized Center of Research Excellence on Sex Differences, with a specific focus on abrupt endocrine disruption, accelerated aging, and Alzheimer’s disease. Dr. Mielke is the past-chair of the Biofluid-Based Biomarker Professional Interest Area under the Alzheimer’s Association, co-Chair of the Society of Women’s Health Alzheimer’s Disease Network, a member of the Food and Drug Administration Peripheral and Central Nervous System Advisory Committee, and Senior Associate Editor of Alzheimer’s and Dementia. She is the PI of several NIH- and Foundation-funded clinical- and epidemiological-based grants. She has published over 200 manuscripts and has presented at multiple national and international conferences and consortiums.